Cohance Lifesciences Ltd Hits Intraday High with 7.44% Surge on 18 Feb 2026

Intraday Trading Highlights

On 18 Feb 2026, Cohance Lifesciences Ltd opened with a gap up of 2.55%, signalling early bullish sentiment among traders. The stock maintained upward momentum throughout the session, eventually touching a day’s high of Rs 333.7, representing an 8.45% gain from the prior close. By the end of the trading day, the stock recorded a day change of 7.44%, significantly outperforming the Sensex, which closed marginally down by 0.02% at 83,437.43 points.

The stock’s performance also eclipsed its sector benchmark, outperforming the Pharmaceuticals & Biotechnology sector by 7.22% on the day. This strong intraday surge contributed to a consecutive two-day gain, with the stock rising 7.97% over this period.

Technical Context and Moving Averages

Despite the strong intraday rally, Cohance Lifesciences Ltd remains trading below its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This indicates that while the stock has shown short-term strength, it continues to face resistance at longer-term technical levels. The gap up opening and sustained buying interest throughout the day suggest a positive shift in trading dynamics, although the stock has yet to break above these critical moving average thresholds.

Market Environment

The broader market environment on 18 Feb 2026 was mixed. The Sensex opened 102.63 points higher but reversed course to close down by 116.16 points, reflecting a cautious market mood. The index remains 3.26% below its 52-week high of 86,159.02, with the 50-day moving average trading above the 200-day moving average, signalling a generally positive medium-term trend for the benchmark despite the day’s weakness.

In contrast to the Sensex’s slight decline, Cohance Lifesciences Ltd’s strong intraday performance stands out as a notable exception within the Pharmaceuticals & Biotechnology sector and the broader market.

Performance Metrics and Longer-Term Trends

While the stock’s intraday gains are impressive, its longer-term performance metrics reveal ongoing challenges. Over the past week, Cohance Lifesciences Ltd has declined by 8.14%, underperforming the Sensex’s 0.95% drop. The one-month performance shows a sharper decline of 23.38%, compared to the Sensex’s marginal 0.16% fall. Over three months, the stock has fallen 45.24%, significantly lagging the Sensex’s 1.46% decrease.

Year-to-date, the stock is down 38.29%, while the Sensex has declined by 2.09%. Over the past year, the stock’s performance has been notably weak, with a 70.22% drop compared to the Sensex’s 9.83% gain. Even over three and five years, Cohance Lifesciences Ltd has underperformed the benchmark, declining 32.40% and 34.18% respectively, while the Sensex has risen 36.78% and 62.57% over the same periods.

These figures underscore the stock’s volatility and the significant gap between its performance and that of the broader market and sector indices.

Mojo Score and Grade Update

Cohance Lifesciences Ltd currently holds a Mojo Score of 30.0, categorised as a Sell grade. This represents an upgrade from its previous Strong Sell rating, which was revised on 20 Jan 2026. The Market Cap Grade stands at 3, reflecting the company’s market capitalisation relative to its peers within the Pharmaceuticals & Biotechnology sector.

The upgrade in grade suggests some improvement in the company’s underlying metrics or market perception, coinciding with the recent positive price action. However, the overall Mojo Score and Sell rating indicate that caution remains warranted given the stock’s historical performance and valuation context.

Summary of Trading Action

The strong intraday performance of Cohance Lifesciences Ltd on 18 Feb 2026, marked by a 7.44% gain and an intraday high of Rs 333.7, reflects a notable shift in trading sentiment. The stock’s ability to outperform both its sector and the broader Sensex index amid a mixed market environment highlights its current momentum.

However, the stock remains below key moving averages and continues to face headwinds in its longer-term price trends. The recent upgrade from Strong Sell to Sell grade indicates some improvement but also signals that the stock is still viewed cautiously within the market framework.

Investors and market participants will likely monitor whether this intraday strength can be sustained and if the stock can break above its moving average resistance levels in the near term.

Unlock special upgrade rates for a limited period. Start Saving Now →